Finance Watch: Clinical-Stage Autoimmune Start-Ups Garner Big Investments
Attovia Raises $105m After Zenas Brings In $200m
Private Company Edition: Attovia will advance two anti-IL-31 programs with its $105m in series B funding, while ImmuNext secured $575m in a Royalty Pharma deal for its Sanofi-partnered drug. Also, Bluejay and Aardvark raised $182m and $85m, respectively, in series C rounds.
